Race Oncology Ltd. (AU:RAC) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Race Oncology Ltd. has submitted the necessary regulatory documents for a Phase 1 clinical trial of their RC220 bisantrene treatment, aimed at combating solid tumors. This trial will explore the safety and efficacy of RC220 in combination with doxorubicin, with patient recruitment expected to begin in Q1 2025. The study, which will take place across multiple sites in Australia, Hong Kong, and South Korea, could pave the way for larger international trials, enhancing treatment options for cancer patients.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.